Timeline
- 1922 Banting and Best use bovine insulin extract on human
- 1923 Eli Lilly and Company (Lilly) produces commercial quantities of bovine insulin
- 1923 Hagedorn founds the Nordisk Insulinlaboratorium in Denmark forerunner of Novo Nordisk
- 1926 Nordisk receives Danish charter to produce insulin as a non-profit
- 1936 Canadians D.M. Scott and A.M. Fisher formulate zinc insulin mixture and license to Novo
- 1936 Hagedorn discovers that adding protamine to insulin prolongs the effect of insulin
- 1946 Nordisk formulates Isophane porcine insulin a.k.a. Neutral Protamine Hagedorn or NPH insulin
- 1946 Nordisk crystallizes a protamine and insulin mixture
- 1950 Nordisk markets NPH insulin
- 1953 Novo formulates Lente porcine and bovine insulins by adding zinc for longer-lasting insulin
- 1978 Genentech produces synthetic 'human' insulin in Escheria coli bacteria using recombinant DNA technology
- 1981 Novo Nordisk chemically and enzymatically converts porcine insulin to 'human' insulin
- 1982 Genentech synthetic 'human' insulin approved, largely thanks to its partnership with Eli Lilly and Company, who shepherded the product through the U.S. Food and Drug Administration (FDA) approval process
- 1983 Lilly produces synthetic, recombinant 'human' insulin, branded Humulin
- 1985 Axel Ullrich sequences the human insulin receptor
- 1988 Novo Nordisk produces synthetic, recombinant 'human' insulin
- 1996 Lilly Humalog "lispro" insulin analogue approved by the U.S. Food and Drug Administration
- 2003 Aventis Lantus "glargine" insulin analogue approved in USA
- 2004 Sanofi Aventis Apidra insulin "glulisine" analogue approved for clinical use in the USA.
- 2006 Novo Nordisk's Levemir "insulin detemir" analogue approved in USA
Read more about this topic: Insulin Analog